ERBB2 and breast carcinoma: Most clinical trials use immunohistochemistry (IHC) 1+, or IHC 2+ and FISH negative as the definition of HER2-low breast cancer and the proportion of people with HER2 low expression is as high as 45%-55% with this diagnostic criteria (14, 15).